Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy

British Journal of Haematology

Volumn 136, Issue 5, 2007, Pages 736-744

  Österborg, Anders ^a   Steegmann, Juan Luis ^b   Hellmann, Andrzej ^c   Couban, Stephen ^d   Mayer, Jiri ^e   Eid, Joseph E ^f  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c MEDICAL UNIVERSITY OF GDANSK   (Poland)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^f HOFFMANN LA ROCHE INC   (United States)

Author keywords

Anaemia; Chemotherapy; Continuous erythropoietin receptor activator (C.E.R.A.); Non Hodgkin's lymphoma; Phase II trial

Indexed keywords

ANTHRACYCLINE; ANTIBODY; ANTINEOPLASTIC AGENT; CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEMOGLOBIN; IRON; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DOSE CALCULATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HEMATOMA; HEMATOPOIESIS; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HUMAN; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NONHODGKIN LYMPHOMA; OPEN STUDY; PARALLEL DESIGN; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; ST SEGMENT DEPRESSION; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; TREATMENT OUTCOME;

EID: 33846950424     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2007.06494.x     Document Type: Article

References (24)

1. Bohlius, J., Langensiepen, S., Schwarzer, G., Seidenfeld, J., Piper, M., Bennett, C. & Engert, A. (2005a) Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis. Journal of the National Cancer Institute, 97, 489-498.
2. Bohlius, J., Wilson, J., Bayliss, S., Djulbegovic, B., Hyde, C., Trelle, S., Weingart, O., Brunskill, S., Sandercock, J., Seidenfeld, J., Piper, M., Langensiepen, S., Schwarzer, G., Bennett, C. & Engert, A. (2005b) Epoetin and darbepoetin to treat cancer patients: updated meta-analysis results (abstract). Blood, 106, 222a, 751.
3. Boogaerts, M., Coiffier, B. & Kainz, C. (2003) Impact of epoetin beta on quality of life in patients with malignant disease. British Journal of Cancer, 88, 988-995.
4. Brandt, M., Lanzendörfer, M., Frische, J., Haselbeck, A. & Jarsch, M. (2006) Different receptor binding activity of C.E.R.A. (continuous erythropoietin receptor activator) compared with epoetin beta determined by surface plasmon resonance and competition assay on UT-7 cells (abstract). Nephrology, Dialysis, Transplantation, 21(Suppl. 4), iv9, SO018.
5. Canon, J.L., Vansteenkiste, J., Bodoky, G., Mateos, M.V., Bastit, L., Ferreira, I., Rossi, G. & Amado, R.G. (2006) Randomized, double-blind, active-controlled trial of every 3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia. Journal of the National Cancer Institute, 98, 273-284.
6. Cazzola, M., Beguin, Y., Kloczko, J., Spicka, I. & Coiffier, B. (2003) Once-weekly epoetin beta is highly effective in treating anaemic patients with lymphoproliferative malignancy and defective endogenous erythropoietin production. British Journal of Haematology, 122, 386-393.
7. Cella, D. (1998) Factors influencing quality of life in cancer patients: anemia and fatigue. Seminars in Oncology, 25(Suppl. 7), 43-46.
8. Coiffier, B., Boogaerts, M., Aapro, M., Huber, M. & Burger, H.-U. (2004) Thromboembolic events in patients with cancer treated with epoetin beta: A meta-analysis of controlled clinical trials (abstract). Annals of Oncology, 15(Suppl. 3), iii221, 840P.
9. Dougherty, F.C., Reigner, B., Jordan, P. & Pannier, A. (2004) Continuous Erythropoiesis Receptor Activator (C.E.R.A.) provides dose-dependent erythropoietic activity with a prolonged half-life in healthy volunteers (abstract). Annals of Oncology, 15(Suppl. 3), iii157, 592P.
10. Glaspy, J., Henry, D., Patel, R., Tchekmedvian, S., Applebaum, S., Berdeaux, D., Lloyd, R., Berg, R., Austin, M., Rossi, G. & Darbepoetin Alfa 20010162 Study Group. (2005) Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. European Journal of Cancer, 41, 1140-1149.
11. Halstenson, C.E., Macres, M., Katz, S.A., Schnieders, J.R., Watanabe, M., Sobota, J.T. & Abraham, P.A. (1991) Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clinical Pharmacology and Therapeutics, 50, 702-712.
12. Haselbeck, A., Reigner, B., Jordan, P., Pannier, A. & Glaspy, J. (2003) Pre-clinical and phase I pharmacokinetic and mode-of-action studies of C.E.R.A. (continuous erythropoiesis receptor activator), a novel erythropoietic agent with an extended serum half-life (abstract). Proceedings of the American Society of Clinical Oncology, 22, 748, 3006.
13. Hedenus, M., Adriansson, M., San Miguel, J., Kramer, M.H., Schipperus, M.R., Juvonen, E., Taylor, K., Belch, A., Altes, A., Martinelli, G., Watson, D., Matcham, J., Rossi, G., Littlewood, T.J. & Darbepoetin Alfa 20000161 Study Group. (2003) Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. British Journal of Haematology, 122, 394-403.
14. Knight, K., Wade, S. & Balducci, L. (2004) Prevalence and outcomes of anemia in cancer: a systematic review of the literature. The American Journal of Medicine, 116(Suppl. 7A), 11S-26S.
15. Kotasek, D., Steger, G., Faught, W., Underhill, C., Poulsen, E., Colowick, A.B., Rossi, G., Mackey, J. & Aranesp 980291 Study Group. (2003) Darbepoetin alfa administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. European Journal of Cancer, 39, 2026-2034.
16. Littlewood, T.J., Bajetta, E., Nortier, J.W., Vercammen, E., Rapoport, B. & Epoetin Alfa Study Group. (2001) Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving non-platinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. Journal of Clinical Oncology, 19, 2865-2874.
17. Ludwig, H., Van Belle, S., Barrett-Lee, P., Birgegard, G., Bokemeyer, C., Gascon, P., Kosmidis, P., Krzakowski, M., Nortier, J., Olmi, P., Schneider, M. & Schrijvers, D. (2004) The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. European Journal of Cancer, 40, 2293-2306.
18. Macdougall, I.C. (2005) C.E.R.A. (continuous erythropoietin receptor activator): a new erythropoiesis-stimulating agent for the treatment of anemia. Current Hematology Reports, 4, 436-440.
19. Morère, J.F. (2004) Role of epoetin in the management of anaemia in patients with lung cancer. Lung Cancer, 46, 149-156.
20. Moullet, I., Salles, G., Ketterer, N., Dumontet, C., Bouafia, F., Neidhart-Berard, E.M., Thieblemont, C., Felman, P. & Coiffier, B. (1998) Frequency and significance of anemia in non-Hodgkin's lymphoma patients. Annals of Oncology, 9, 1109-1115.
21. Österborg, A., Brandberg, Y., Molostova, V., Iosava, G., Abdulkadyrov, K., Hedenus, M., Messinger, D. & Epoetin Beta Hematology Study Group. (2002) Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. Journal of Clinical Oncology, 20, 2486-2494.
22. Österborg, A., Hellmann, A., Steegmann, J.L. & Couban, S. (2004) C.E.R.A. (Continuous Erythropoiesis Receptor Activator): dose-response trial of subcutaneous (SC) administration once every 3 weeks (Q3W) to patients with aggressive non-Hodgkin's lymphoma and anemia receiving chemotherapy (abstract). Blood, 104, 142b, 4225.
23. Reigner, B., Jordan, P., Pannier, A. & Glaspy, J. (2003) C.E.R.A. (continuous erythropoiesis receptor activator), a novel erythropoietic agent: dose-dependent response in phase I studies (abstract). Proceedings of the American Society of Clinical Oncology, 22, 732, 2943.
24. Thomas, M.L. (1998) Impact of anemia and fatigue on quality of life in cancer patients: a brief review. Medical Oncology, 15(Suppl. 1), S3-S7.